<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110599</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC-Nr. 2021-00941</org_study_id>
    <nct_id>NCT05110599</nct_id>
  </id_info>
  <brief_title>Bryophyllum Pinnatum Treatment of Anxiety Related to Preterm Labour</brief_title>
  <official_title>Bryophyllum Pinnatum Treatment of Anxiety Related to Preterm Labour: a Randomised, Double-blind, Placebo-controlled Study as Investigator-Initiated Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Haslinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present IIT (Investigator-Initiated Trial) study is a prospective, randomised,&#xD;
      placebo-controlled, double blind trial.&#xD;
&#xD;
      Women with preterm labour, who undergo a 48 h tocolysis cycle and are then clinically stable,&#xD;
      can be recruited for the study. Participants will take study medication for up to 9 weeks&#xD;
      (until birth or end of premature birth period) and fill out a questionnaire at 3 time points&#xD;
      (at baseline, after 1 week and after 2 weeks) to assess state of anxiety and sleep quality.&#xD;
      Furthermore, information regarding adverse events and the further course of the pregnancy are&#xD;
      recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm birth is one of the leading causes for mortality and morbidity in newborns and&#xD;
      preterm contractions are the cause of a considerable part of preterm deliveries. In the&#xD;
      treatment of preterm labour, tocolytic medications are often used that are associated with&#xD;
      numerous side effects for the pregnant woman, which limits their use in time. Preparations&#xD;
      from Bryophyllum pinnatum, which demonstrated excellent tolerability, constitute a safe&#xD;
      alternative for tocolytic treatment. It was introduced as an alternative tocolytic by&#xD;
      anthroposophic medicine in Europe and is used as a monotherapy or add-on therapy for preterm&#xD;
      labour in many perinatal clinics in Switzerland today. In vitro studies support the use of B.&#xD;
      pinnatum as a tocolytic.&#xD;
&#xD;
      In addition, there are also limited options for the treatment of mental disorders and sleep&#xD;
      disturbances during pregnancy. Anxiety plays a major role in the development of preterm&#xD;
      labour and often leads to administration of tocolytics longer than necessary. Preparations&#xD;
      from B. pinnatum have traditionally been in the treatment of anxiety. Improvements of sleep&#xD;
      quality in pregnant women during treatment with B. pinnatum preparations were already shown&#xD;
      in previous studies.&#xD;
&#xD;
      This exploratory study aims at investigating the effects of B. pinnatum as a follow-up&#xD;
      therapy to a 48-hour tocolytic cycle with standard medications, focusing on reducing anxiety&#xD;
      but also on pregnancy prolongation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>After 48 h tocolysis cycle patients are randomized to the Bryophyllum group or the placebo group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in situational state of anxiety</measure>
    <time_frame>Assessment before treatment, after 1 week and after 2 weeks</time_frame>
    <description>assessed with State-Trait-Anxiety-Inventory (STAI) values from 20 to 80, higher scores indicating worse state of anxiety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in situational state of anxiety</measure>
    <time_frame>assessment before treatment, after 1 week and after 2 weeks</time_frame>
    <description>assessed with Pregnancy-related Anxiety Questionnaire Revised 2 (PRAQ-R2) values from 10 to 50, higher scores indicating worse state of anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in sleep quality</measure>
    <time_frame>assessment before treatment, after 1 week and after 2 weeks</time_frame>
    <description>assessed with Pittsburgh Sleep Quality Index (PSQI) values from 0 to 21, higher scores indicating worse sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalisation days</measure>
    <time_frame>from randomisation till birth or end of preterm period, whichever came first, up to 9 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reached gestational age</measure>
    <time_frame>at birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of Adverse Events</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>occurence of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Preterm Labor</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Bryophyllum 50%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants of the verum group take Bryophyllum 50% chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for a maximum of 9 weeks. The duration of the therapy is individual for each patient, since the therapy ends at the end of preterm period or at birth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants of the control group take Placebo chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for a maximum of 9 weeks. The duration of the therapy is individual for each patient, since the therapy ends at the end of preterm period or at birth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bryophyllum 50% chewable tablets</intervention_name>
    <description>Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g</description>
    <arm_group_label>Bryophyllum 50%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose with adaption in appearance and tast</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single pregnancy&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  Stable clinical situation after complete tocolysis cycle of 48 h without indication&#xD;
             for continuation of tocolysis&#xD;
&#xD;
          -  Gestational age at randomisation &gt;28 weeks (28+0) and &lt;34 weeks (33+6)&#xD;
&#xD;
          -  Good German or English skills&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Early premature rupture of the membranes (PPROM)&#xD;
&#xD;
          -  Factors that make soon delivery likely (pre-eclampsia, suspect cardiotocography,&#xD;
             clinical signs of an amniotic infection)&#xD;
&#xD;
          -  Body temperature &gt;38Â°C&#xD;
&#xD;
          -  Cervical length &lt; 10 mm at beginning of tocolysis&#xD;
&#xD;
          -  Contraindication for B. pinnatum, lactose or wheat protein allergy&#xD;
&#xD;
          -  Taking Bryophyllum 50% chewable tablets or powder during the last 30 days&#xD;
&#xD;
          -  Taking psychotropic drugs (Benzodiazepines, antidepressants, neuroleptics)&#xD;
&#xD;
          -  Diagnosed psychiatric disease (depression, anxiety disorder, adaptation disorder,&#xD;
             post- traumatic stress disorder, bipolar disorder)&#xD;
&#xD;
          -  Active participation in another interventional study during the last 4 weeks&#xD;
&#xD;
          -  Known or suspected non-compliance with study protocol&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Haslinger, PD Dr. med.</last_name>
    <phone>+41 44 255 46 13</phone>
    <email>christian.haslinger@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Paula SimÃµes-WÃ¼st, PD Dr. phil.</last_name>
    <phone>+41 44 255 51 31</phone>
    <email>anapaula.simoes-wuest@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Haslinger, MD</last_name>
      <email>christian.haslinger@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>FÃ¼rer K, SimÃµes-WÃ¼st AP, von Mandach U, Hamburger M, Potterat O. Bryophyllum pinnatum and Related Species Used in Anthroposophic Medicine: Constituents, Pharmacological Activities, and Clinical Efficacy. Planta Med. 2016 Jul;82(11-12):930-41. doi: 10.1055/s-0042-106727. Epub 2016 May 24. Review.</citation>
    <PMID>27220081</PMID>
  </reference>
  <reference>
    <citation>Plangger N, Rist L, Zimmermann R, von Mandach U. Intravenous tocolysis with Bryophyllum pinnatum is better tolerated than beta-agonist application. Eur J Obstet Gynecol Reprod Biol. 2006 Feb 1;124(2):168-72. Epub 2005 Jul 26.</citation>
    <PMID>16051414</PMID>
  </reference>
  <reference>
    <citation>SimÃµes-WÃ¼st AP, Jeschke E, Mennet M, Schnelle M, Matthes H, von Mandach U. Prescribing pattern of Bryophyllum preparations among a network of anthroposophic physicians. Forsch Komplementmed. 2012;19(6):293-301. doi: 10.1159/000345841. Epub 2012 Dec 17.</citation>
    <PMID>23343584</PMID>
  </reference>
  <reference>
    <citation>Lambrigger-Steiner C, SimÃµes-WÃ¼st AP, Kuck A, FÃ¼rer K, Hamburger M, von Mandach U. Sleep quality in pregnancy during treatment with Bryophyllum pinnatum: an observational study. Phytomedicine. 2014 Apr 15;21(5):753-7. doi: 10.1016/j.phymed.2013.11.003. Epub 2013 Dec 25.</citation>
    <PMID>24373544</PMID>
  </reference>
  <reference>
    <citation>SimÃµes-WÃ¼st AP, Lapaire O, HÃ¶sli I, WÃ¤chter R, FÃ¼rer K, Schnelle M, Mennet-von Eiff M, Seifert B, von Mandach U. Two Randomised Clinical Trials on the Use of Bryophyllum pinnatum in Preterm Labour: Results after Early Discontinuation. Complement Med Res. 2018;25(4):269-273. doi: 10.1159/000487431. Epub 2018 Jun 22.</citation>
    <PMID>29945146</PMID>
  </reference>
  <reference>
    <citation>Santos S, Haslinger C, Klaic K, Faleschini MT, Mennet M, Potterat O, von Mandach U, Hamburger M, SimÃµes-WÃ¼st AP. A Bufadienolide-Enriched Fraction of Bryophyllum pinnatum Inhibits Human Myometrial Contractility In Vitro. Planta Med. 2019 Mar;85(5):385-393. doi: 10.1055/a-0810-7704. Epub 2018 Dec 18.</citation>
    <PMID>30562827</PMID>
  </reference>
  <reference>
    <citation>Santos S, Haslinger C, Mennet M, von Mandach U, Hamburger M, SimÃµes-WÃ¼st AP. Bryophyllum pinnatum enhances the inhibitory effect of atosiban and nifedipine on human myometrial contractility: an in vitro study. BMC Complement Altern Med. 2019 Nov 4;19(1):292. doi: 10.1186/s12906-019-2711-5.</citation>
    <PMID>31685022</PMID>
  </reference>
  <reference>
    <citation>Santos S, Zurfluh L, Mennet M, Potterat O, von Mandach U, Hamburger M, SimÃµes-WÃ¼st AP. Bryophyllum pinnatum Compounds Inhibit Oxytocin-Induced Signaling Pathways in Human Myometrial Cells. Front Pharmacol. 2021 Feb 18;12:632986. doi: 10.3389/fphar.2021.632986. eCollection 2021.</citation>
    <PMID>33679416</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Christian Haslinger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bryophyllum pinnatum</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Preterm labor</keyword>
  <keyword>Sleep quality</keyword>
  <keyword>Phytotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

